Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open‐label, randomized controlled trial (BEYOND VII)-Reference-Cited by-同舟云学术

Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open‐label, randomized controlled trial (BEYOND VII)

Published:2020-02-18 Issue:5 Volume:22 Page:838-846
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ji Linong¹^ORCID,Wan Hailong²,Wen Binhong³,Wang Xueying⁴,Wang Junfen⁵,Bian Rongwen⁶,Pang Wuyan⁷,Tian Jian⁸,Wang Yan⁹,Bian Fang¹⁰,Gao Zhengnan¹¹,Condoleon Alex¹²,Feng Wei¹³,Zhang Xia¹³,Cui Nan¹³

Affiliation:

1. Department of Endocrinology and MetabolismPeking University People's Hospital Beijing China

2. Department of Endocrinology, Panjin Central Hospital Panjin China

3. Department of Endocrinology, People's Hospital of Liaoning Province Liaoning China

4. Department of Endocrinology, Jinzhou Central Hospital Jinzhou China

5. Department of Endocrinology, Second Hospital of Shijiazhuang Shijiazhuang China

6. Department of Endocrinology and MetabolismJiangsu Province Institute of Geriatrics Nanjing Jiangsu China

7. Department of Endocrinology and MetabolismHuaihe Hospital of Henan University Kaifeng Henan China

8. Department of Endocrinology and MetabolismCentral Hospital Affiliated to Shenyang Medical College Shenyang China

9. Department of Endocrinology, Second Hospital of Chaoyang City Chaoyang City China

10. Department of Endocrinology, Cangzhou People's Hospital Cangzhou China

11. Department of Endocrinology and MetabolismDalian Municipal Central Hospital Affiliated of Dalian Medical University Dalian Liaoning China

12. Sanofi, Paris France

13. Sanofi Shanghai China

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13967

Reference33 articles.

1. Standards of care for type 2 diabetes in China

2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Multifaceted Determinants for Achieving Glycemic Control

4. Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients

5. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review;BMJ Open Diabetes Research & Care;2024-05

2. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial;Nature Medicine;2023-05-25

3. Use of basal insulin in the management of adults with type 2 diabetes: An Asia‐Pacific evidence‐based clinical practice guideline;Journal of Diabetes;2023-04-23

4. Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis;Journal of Diabetes;2023-04-10

5. Time for Using Machine Learning for Dose Guidance in Titration of People With Type 2 Diabetes? A Systematic Review of Basal Insulin Dose Guidance;Journal of Diabetes Science and Technology;2022-12-23